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Background {#jir12587-sec-0005}
==========

Sleep difficulties affect the amount, quality and timing of sleep (World Health Organisation [1992](#jir12587-bib-0058){ref-type="ref"}) and can affect up to 30% of the general population (Ferrie, Kumari, Salo, Singh‐Manoux & Kivimäki [2011](#jir12587-bib-0012){ref-type="ref"}). The implementation of evidence‐based sleep intervention strategies can help to reduce some of the short‐term and long‐term health and behavioural consequences of poor sleep (Cappuccio, D\'Elia, Strazzullo & Miller [2010](#jir12587-bib-0010){ref-type="ref"}; Cappuccio, Cooper, Delia, Strazzullo & Miller [2011](#jir12587-bib-0008){ref-type="ref"}; Irwin, Olmstead & Carroll [2016](#jir12587-bib-0021){ref-type="ref"}). However, intervention strategies that are advocated for in the general population (e.g. cognitive behavioural therapy) may not always be appropriate or accessible for specialised populations such as adults with an intellectual disability (ID).

A systematic review of the prevalence of sleep difficulties amongst adults with ID identified that 32% experienced multiple sleep difficulties (Boyle *et al*. [2010](#jir12587-bib-0005){ref-type="ref"} *;* Van de Wouw, Evenhuis & Echteld [2012](#jir12587-bib-0049){ref-type="ref"}). Using the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition diagnostic criteria for insomnia, the prevalence was found to increase with age (Phillips & Mannino [2005](#jir12587-bib-0039){ref-type="ref"}). Previous work also indicates that adults with an ID have significantly less stable and more fragmented sleep than adults from the general population (Maaskant, van de Wouw, van Wijck, Evenhuis & Echteld [2013](#jir12587-bib-0027){ref-type="ref"}). Furthermore, evidence indicates that individuals with higher severity or co‐morbid disabilities are at an increased likelihood of having sleep difficulties (Lindblom *et al*. [2001](#jir12587-bib-0026){ref-type="ref"}).

In addition to the broad health consequences of sleep difficulties, there is evidence that adults with an ID can also exhibit challenging behaviours as a result of issues with their sleep (Lenjavi, Ahuja, Touchette & Sandman [2010](#jir12587-bib-0025){ref-type="ref"}). In particular, adults with higher support and communication needs present with an increased frequency of behaviours that challenge as a result of difficulties with their sleep (Vollmer & Smith [1996](#jir12587-bib-0052){ref-type="ref"}; Matson, González, Terlonge, Thorson & Laud [2007](#jir12587-bib-0031){ref-type="ref"}; Lenjavi *et al*. [2010](#jir12587-bib-0025){ref-type="ref"}). These challenging behaviours are associated with a higher cost of support and higher utilisation rates of day centres and specialists in community teams (Knapp, Comas‐herrera, Beecham & Pendaries [2005](#jir12587-bib-0023){ref-type="ref"}; Griffith & Hastings [2014](#jir12587-bib-0014){ref-type="ref"}).

Despite evidence supporting the prevalence and issues associated with sleep difficulties in adults with an ID, there is a need for more clarity around the evidence that supports existing recommendations. Within the UK, the National Institute for Health and Care Excellence ([2015](#jir12587-bib-0035){ref-type="ref"}) recommends the use of functional analysis of problem sleep behaviours and structured bedtime routines prior to medication such as melatonin. However, the evidence base underpinning the use of this approach has primarily focused on studies involving children (O\'Reilly [1995](#jir12587-bib-0037){ref-type="ref"}; Hanley, Iwata & McCord [2003](#jir12587-bib-0017){ref-type="ref"}). Within the UK, the use of melatonin for adults with an ID is currently licenced for those aged 55 or over and for a maximum of 13 weeks (National Institute for Health and Care Excellence [2015](#jir12587-bib-0035){ref-type="ref"}); thus, it is a commonly used intervention for insomnia.

Interventions typically utilised following assessment involve sleep hygiene and stimulus control. Sleep hygiene focuses on lifestyle and environmental factors such as reducing the consumption of caffeine, exercising regularly, avoiding daytime naps and managing stress to promote sleep (Irish, Kline, Gunn, Buysse & Hall [2015](#jir12587-bib-0020){ref-type="ref"}). Stimulus control reduces stimuli that promote wakefulness in the sleeping environment. Examples include avoiding the use of a television in the sleep environment and leaving the sleeping environment after 15 min if unable to sleep until feeling sleepy (Gunning & Espie [2003](#jir12587-bib-0015){ref-type="ref"}). Other interventions that may be effective in the adult population include optimal scheduling of sleep, light therapy and a multicomponent behaviour plan based on the function of sleep disrupting behaviour (Van de Wouw *et al*. [2012](#jir12587-bib-0049){ref-type="ref"}).

Existing syntheses on the effectiveness of sleep interventions in ID combine results from adult and child populations (Van de Wouw *et al*. [2012](#jir12587-bib-0049){ref-type="ref"}; Priday, Byrne & Totsika [2017](#jir12587-bib-0040){ref-type="ref"}). Therefore, there is a need for research that systematically examines the effectiveness of sleep interventions for adults with an ID. The aim of this work was to systematically determine the effectiveness of existing sleep interventions for adults aged 18+ with an ID.

Methods {#jir12587-sec-0006}
=======

Search strategy {#jir12587-sec-0007}
---------------

A systematic literature search was performed in June 2017 using search terms categorised into 'intellectual disability', 'sleep' and 'adult' (Table [1](#jir12587-tbl-0001){ref-type="table"}). Search terms were combined using the Boolean operators 'and' between categories and 'or' within categories. Only those papers published between January 1997 and August 2017 were considered in the first search. The 20‐year time frame was chosen based on the American Academy of Sleep Medicine\'s conclusion that actigraphy was a useful research tool for the study of sleep in 1995 (Martin & Hakim [2011](#jir12587-bib-0030){ref-type="ref"}). Only papers published in English were reviewed. The search terms were entered into the following electronic databases: BNI (Proquest, Michigan, USA), CINAHL (Elsevier, Amsterdam, Netherland), HBE (EBSCO, Ipswich, USA), HMIC (OVID, Leeds, UK), MEDLINE (EBSCO, Ipswich, USA; and Proquest, Michigan, USA), PsychArticles (American Psychological Association, Washington DC, USA), PsychINFO (American Psychological Association, Washington DC, USA) and PubMed (United States National Library of Medicine, Bethesda, MD, USA). A second search was completed using the criteria published in June 2017 in specialised journals including *Advances in Psychiatric Treatment*, *The Psychiatrist* and *British Journal of Psychiatry* (see Table [1](#jir12587-tbl-0001){ref-type="table"} for a list of all the search terms used). A third search was completed to review papers published between June 2017 and August 2018. References of the included studies were also reviewed.

###### 

Search strategy (Boolean operators 'or' and 'and' between columns)

  Intellectual disability                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Sleep                                                                                                                                                               Adult (\>18 years)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------
  intellectual disability, intellectually retarded, intellectually disabled, mental disability, mentally disabled, idiocy, mental deficiency, learning disability, learning disorder, learning disturbance, developmental disability, mental handicap, mentally handicap, intellectual handicap, intellectually handicap, Down syndrome, mental incapacity, intellectual incapacity and oligophrenia    sleep, sleep disorder, insomnia, dyssomnia, parasomnia, parasomnias, somnolence, hypersomnia, circadian, wake, ultradian, night terrors, sleepwalking, somnambulism, nightmares, sleep apnoea, nocturnal, hypnotics, soporific, REM, nap, narcolepsy, snoring and sleep paralysis   adult, middle aged, ageing, elderly, geriatric, old and senior

The protocol is available on PROSPERO with ID: CRD42017076262 (<https://www.crd.york.ac.uk/PROSPERO/display_record.php>? RecordID = 76262).

Selection criteria {#jir12587-sec-0008}
------------------

All studies published in a peer‐reviewed journal with experimental designs were considered; thus, studies that did not provide information on a study design or were neither quantitative nor narrative in nature were not included. The type of experimental designs used included A‐B designs, randomised controlled trials and multiple baseline designs. Studies were selected if they attempted to formally evaluate the change in sleep following sleep interventions in adults aged 18 and over with a diagnosed ID. We included experimental studies, case series designs and case reports. ID had to be identified using local or international diagnostic criteria and terminology. Studies were required to assess sleep difficulties in adults with an ID although no restrictions were placed on the assessments used to evaluate sleep difficulties.

In studies that involved both children and adults, information on sleep for the adult participants had to be separately reported in the text or a table/figure (for at least one participant). Articles with a reported change in sleep noted as a secondary effect were excluded such as mental health problems (i.e. mood disorder, anxiety disorder, psychotic disorder, amnestic disorder, attention‐deficit hyperactivity disorder or personality disorder; Schutte‐Rodin, Broch, Buysse, Dorsey & Sateia [2008](#jir12587-bib-0044){ref-type="ref"}).

Selection process {#jir12587-sec-0009}
-----------------

Two reviewers (P. S. and N. M.) independently screened the articles for eligibility (Figure [1](#jir12587-fig-0001){ref-type="fig"}). Disagreements in identified articles were resolved through consensus or failing this with the help of another reviewer (S. P.).

![Preferred Reporting Items for Systematic Reviews and Meta‐Analyses flow chart of selection.](JIR-63-372-g001){#jir12587-fig-0001}

Articles that included children and adults without reporting adult data separately were contacted via email (*n* = 3). Those who subsequently provided adult‐only data were included in the review (*n* = 2).

Data extraction and management {#jir12587-sec-0010}
------------------------------

The following data were collated by the first researcher (P. S.) of the agreed journal articles for inclusion (Table [2](#jir12587-tbl-0002){ref-type="table"}): Participant characteristics: number of participants, study population (country, age, gender)Study characteristics: study designIntellectual disability criteriaSleep difficulty criteriaInterventions used in the studyData on the efficacy of intervention

###### 

Study characteristics

  Authors                                                                              Sample                                 Study design   ID[†](#jir12587-note-0002){ref-type="fn"} criteria   Sleep difficulty criteria   Intervention type                                 Efficacy of intervention                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  ------------------------------------------------------------------------------------ -------------------------------------- -------------- ---------------------------------------------------- --------------------------- ------------------------------------------------- --------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Braam, Didden, Smits, and Curfs ([2008](#jir12587-bib-0006){ref-type="ref"})         51 (21 adults)                         Netherlands    20--78 (adult only)                                  66.7                        Randomised, placebo‐controlled study              Level of ID based on the age equivalent on the Social Functioning Scale for the Mentally Retarded   Sleep onset latency of 30 min or more, two or more periods of night waking\'s that lasted 45 min each night, five or more night waking\'s lasting more than 15 min each, during at least five nights each week. Present for the duration of at least 1 year   Melatonin (5 mg) or placebo                                                                                                                     Significant change in sleep onset time (*P* \< 0.01), decrease in sleep onset latency (*P* \< 0.01), decrease in number of night wakes per night (*P* \< 0.05), duration in night wakes (*P* \< 0.05) and increase in total sleep time (*P* \< 0.05)
  Didden, Curfs, van Driel, and de Moor ([2002](#jir12587-bib-0011){ref-type="ref"})   4 (1 adult)                            Netherlands    25 (adult only)                                      75                          Case series (multiple baseline design)            Not given                                                                                           'Wake up several times'                                                                                                                                                                                                                                       Functional assessment and recommendations (extinction)                                                                                          Visual analysis of data and reported improvement in night time disruptive behaviour
  Gunning and Espie ([2003](#jir12587-bib-0015){ref-type="ref"})                       155 (start) -- \>9 (completed)         UK             20--47                                               45.8                        Case series (multiple baseline design)            From medical history                                                                                Structured assessment to diagnose sleep problems within framework of ICSD‐R[‡](#jir12587-note-0003){ref-type="fn"}                                                                                                                                            Optimal scheduling, sleep hygiene, stimulus control, relaxation, light therapy and cognitive behaviour therapy                                  Improvements to target variables found for six participants (*P* \< 0.05)
  Hare, Dodd, and Arshad ([2008](#jir12587-bib-0018){ref-type="ref"})                  3                                      UK             43--69                                               66.6                        Case series (AB design)                           The Casemix Scale                                                                                   Difficulty falling asleep, broken sleep, waking up during the night without any reason, waking in the early hours of the morning, reversal of sleep pattern, sleeping during the day and awake at night                                                       Melatonin (6--12 mg[§](#jir12587-note-0004){ref-type="fn"})                                                                                     Improvement reported in sleep duration, however, not clinically significant
  Hylkema and Vlaskamp ([2009](#jir12587-bib-0019){ref-type="ref"})                    41 (34 adults)                         Netherlands    19--66 (adult only)                                  63.4                        Case series (AB design)                           Level of ID categorised into moderate to severe (unclear diagnostic criteria)                       Registration form with why it was thought had a sleep difficulty, sleep hygiene checklist, survey of activities, sleep diary and actigraphy                                                                                                                   MDT[¶](#jir12587-note-0005){ref-type="fn"} decided intervention, varying type: activity, different daily routines, sleep scheduling and other   Improvement in sleep efficiency and latency (*P* \< 0.001)
  Richings and Feroz‐Nainar ([2010](#jir12587-bib-0041){ref-type="ref"})               3                                      UK             32--74                                               33.3                        Case series (series of individual case studies)   Not given                                                                                           In text, not written separately: 'poor sleep', 'sleeping poorly', 'difficulty falling asleep'                                                                                                                                                                 Melatonin (2.5--10 mg)                                                                                                                          Increased agitation reported following use of melatonin
  Short and Carpenter ([1998](#jir12587-bib-0045){ref-type="ref"})                     1                                      UK             34                                                   100                         Case study                                        Not given                                                                                           'Difficulty getting off to sleep and waking frequently during the early hours of the morning, excessive daytime drowsiness and lethargy'                                                                                                                      Light therapy                                                                                                                                   Sleep improvement reported
  Stenfert‐Kroese and Thomas ([2006](#jir12587-bib-0046){ref-type="ref"})              2                                      UK             18--24                                               0                           Case series (AB design)                           Full Scale IQ[††](#jir12587-note-0006){ref-type="fn"}                                               Verbally reported. No formal assessment                                                                                                                                                                                                                       Imagery rehearsal therapy                                                                                                                       Participant verbally reported decrease in nightmares
  Ward, Nanjappa, Hinder, and Roy ([2015](#jir12587-bib-0054){ref-type="ref"})         109 (23 adults, 2 adults without ID)   UK             18--67                                               65                          Retrospective case note analysis                  ICD‐10 (categorised as mild, moderate, severe or profound)                                          Type reported: 'generally disturbed sleep, initial insomnia, early morning awakening, both initial insomnia and early morning awakening, reversed sleep pattern, awake all night, indication not recorded'                                                    Melatonin (2.5--10 mg)                                                                                                                          Sleep improvement reported in 15 of 23 participants

No *P* values are shown when not presented in paper.

Intellectual disability.

International Classification of Sleep Disorders -- Revised.

Milligrams.

Multi‐disciplinary team.

Intelligence quotient.

Quality assessment {#jir12587-sec-0011}
------------------

Quality assessment was completed by three researchers separately (P. S., N. M. and S. P.). The quality of each study and its most relevant study result were assessed using the Risk Of Bias In Non‐randomised Studies -- of Interventions tool (ROBINS‐I; Sterne *et al*. [2016](#jir12587-bib-0047){ref-type="ref"}). The ROBINS‐I is a framework for assessing the risk of bias that may arise from confounding by selection of participants into the study, measurement of interventions, departures from intended interventions, missing data, measurement of outcomes and selection of reported results. Each domain is determined as having low, moderate, serious or critical risk of bias. The overall risk of bias was judged as the most severe risk of bias found in any domain. The exact interrater agreement between researchers of the first quality assessment completion was 95%. Reporting of the systematic review followed Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (Moher *et al*. [2009](#jir12587-bib-0059){ref-type="ref"}) guidelines.

Results {#jir12587-sec-0012}
=======

The initial search identified 725 articles. Once articles had been screened, nine were included in the systematic review. The main reasons for excluding articles following abstract review included the study not containing an intervention and/or having participants under 18. Figure [1](#jir12587-fig-0001){ref-type="fig"} represents the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses flow chart of the study selection. Table [2](#jir12587-tbl-0002){ref-type="table"} is a summary of the study design, measurement of sleep difficulties used and interventions in the identified studies. Sixteen studies were excluded following a full text review. Reasons for exclusion following full text review included no sleep intervention (*N* = 5), mental health difficulty as the primary intervention (*N* = 4), literature review (*N* = 2), physical health condition (*N* = 2), no ID (*N* = 1), adult outcomes not separated from younger participants even after contacting the authors (*N* = 1) and article not published in English (*N* = 1).

Of the nine articles included, risk of bias was evaluated. Levels of risk across the six domains are summarised in Table [3](#jir12587-tbl-0003){ref-type="table"}. The overall risk of bias identified one study that had a low risk (Braam *et al*. [2008](#jir12587-bib-0006){ref-type="ref"}), two with serious risk (Short & Carpenter [1998](#jir12587-bib-0045){ref-type="ref"}; Gunning & Espie [2003](#jir12587-bib-0015){ref-type="ref"}) and six with critical risk of bias (Didden *et al*. [2002](#jir12587-bib-0011){ref-type="ref"}; Stenfert‐Kroese & Thomas [2006](#jir12587-bib-0046){ref-type="ref"}; Hare *et al*. [2008](#jir12587-bib-0018){ref-type="ref"}; Hylkema & Vlaskamp [2009](#jir12587-bib-0019){ref-type="ref"}; Richings & Feroz‐Nainar [2010](#jir12587-bib-0041){ref-type="ref"}; Ward *et al*. [2015](#jir12587-bib-0054){ref-type="ref"}).

###### 

ROBINS‐I risk of bias assessment (low, moderate, serious, critical, no info)

  Authors                                                                   Confounding   Selection   Measurement of intervention   Missing data   Measurement of outcomes   Reported result   Overall risk of bias
  ------------------------------------------------------------------------- ------------- ----------- ----------------------------- -------------- ------------------------- ----------------- ----------------------
  Braam *et al*. ([2008](#jir12587-bib-0006){ref-type="ref"})               Low           Low         Low                           Low            Low                       Low               Low
  Didden *et al*. ([2002](#jir12587-bib-0011){ref-type="ref"})              Critical      Serious     Serious                       Critical       Serious                   Low               Critical
  Gunning and Espie ([2003](#jir12587-bib-0015){ref-type="ref"})            Moderate      Low         Serious                       Serious        Serious                   Low               Serious
  Hare *et al*. ([2008](#jir12587-bib-0018){ref-type="ref"})                Critical      Moderate    Serious                       Low            Serious                   No Info           Critical
  Hylkema and Vlaskamp ([2009](#jir12587-bib-0019){ref-type="ref"})         Critical      Serious     Critical                      Moderate       Serious                   Moderate          Critical
  Richings and Feroz‐Nainar ([2010](#jir12587-bib-0041){ref-type="ref"})    Critical      Low         Serious                       Critical       No Info                   Critical          Critical
  Short and Carpenter ([1998](#jir12587-bib-0045){ref-type="ref"})          Serious       Low         Serious                       No Info        No Info                   No Info           Serious
  Stenfert‐Kroese and Thomas ([2006](#jir12587-bib-0046){ref-type="ref"})   Critical      No Info     Serious                       Serious        Critical                  Serious           Critical
  Ward *et al*. ([2015](#jir12587-bib-0054){ref-type="ref"})                Critical      Critical    Critical                      Moderate       Critical                  Serious           Critical

ROBINS‐I, Risk Of Bias In Non‐randomised Studies -- of Interventions.

Study characteristics {#jir12587-sec-0013}
---------------------

The number of adult participants in nine sleep studies varied from 1 to 34 (mean = 10). The total number of adult participants across studies was 97. The age range of the participants included was from 18 to 78 years (mean = 41 years). Severity of ID across all studies included mild (*N* = 6), moderate (*N* = 17), severe (*N* = 34), profound (*N* = 16), IQ 55--69 (*N* = 2) and not reported (*N* = 22). Of the 22 not reported, causes of ID included Down syndrome (*N* = 4), congenital rubella (*N* = 2), trauma (*N* = 1), Bardet--Biedl syndrome (*N* = 1), encephalitis 9 MND (*N* = 2), Prader--Willi syndrome (*N* = 1), hypothyroidism (*N* = 1) and perinatal problems (*N* = 1) and unknown (*N* = 9). Six studies were completed in the UK and three in the Netherlands.

Experimental designs included a randomised, placebo‐controlled study (*N* = 1; Braam *et al*. [2008](#jir12587-bib-0006){ref-type="ref"}), case series (*N* = 6; Short & Carpenter [1998](#jir12587-bib-0045){ref-type="ref"}; Gunning & Espie [2003](#jir12587-bib-0015){ref-type="ref"}; Stenfert‐Kroese & Thomas [2006](#jir12587-bib-0046){ref-type="ref"}; Hare *et al*. [2008](#jir12587-bib-0018){ref-type="ref"}; Hylkema & Vlaskamp [2009](#jir12587-bib-0019){ref-type="ref"}; Richings & Feroz‐Nainar [2010](#jir12587-bib-0041){ref-type="ref"}), case study (*N* = 1; Didden *et al*. [2002](#jir12587-bib-0011){ref-type="ref"}) and retrospective case note analysis (*N* = 1; Ward *et al*. [2015](#jir12587-bib-0054){ref-type="ref"}). Other medications (including aripiprazole, citalopram, carbamazepine, sodium valproate, diazepam, lamotrigine and cisapride) that participants were taking was reported in nine participants out of 97 (Short & Carpenter [1998](#jir12587-bib-0045){ref-type="ref"}; Hare *et al*. [2008](#jir12587-bib-0018){ref-type="ref"}; Richings & Feroz‐Nainar [2010](#jir12587-bib-0041){ref-type="ref"}). Nineteen participants were reported to have epilepsy, 19 participants diagnosed with autism and one had a diagnosis of attention‐deficit hyperactivity disorder. Visual impairment was reported in eight participants across all studies despite sampling not purposefully identifying this cohort.

Identification of a sleep difficulty {#jir12587-sec-0014}
------------------------------------

One study assessed the type of sleep difficulty using a questionnaire created by the author based on the International Classification of Sleep Disorders Revised (Gunning & Espie [2003](#jir12587-bib-0015){ref-type="ref"}). One study used a combination of factors including a sleep diary, actigraphy, screening questionnaire and activity checklist (Hylkema & Vlaskamp [2009](#jir12587-bib-0019){ref-type="ref"}). Braam *et al*. ([2008](#jir12587-bib-0006){ref-type="ref"}) utilised a sleep diary completed by family or carers to assess the sleep difficulty measuring sleep onset latency, sleep onset time, wake time, total sleep time, number and duration of night wakes. Five studies used verbal report of the individuals being assessed or their carers including sleep onset latency, night waking or subjective quality such as *poor sleep* (Short & Carpenter [1998](#jir12587-bib-0045){ref-type="ref"}; Didden *et al*. [2002](#jir12587-bib-0011){ref-type="ref"}; Stenfert‐Kroese & Thomas [2006](#jir12587-bib-0046){ref-type="ref"}; Hare *et al*. [2008](#jir12587-bib-0018){ref-type="ref"}; Richings & Feroz‐Nainar [2010](#jir12587-bib-0041){ref-type="ref"}; Ward *et al*. [2015](#jir12587-bib-0054){ref-type="ref"}).

Measurement of sleep difficulties {#jir12587-sec-0015}
---------------------------------

A Cambridge Neurotechnology Actiwatch was used to measure duration sleeping, duration awake, sleep efficiency, number of sleep bouts, number of wake bouts, fragmentation index and hours of sleep onset latency in two studies (Hare *et al*. [2008](#jir12587-bib-0018){ref-type="ref"}; Hylkema & Vlaskamp [2009](#jir12587-bib-0019){ref-type="ref"}). Didden *et al*. ([2002](#jir12587-bib-0011){ref-type="ref"}) reported number of minutes of behaviours associated with night‐time disruption caused using an individualised monitoring form. Gunning and Espie ([2003](#jir12587-bib-0015){ref-type="ref"}) reported different measurement types across all participants in the study including sleep onset latency, night wakes, total sleep time, caffeine consumption and number of episodes of night bedclothes removal using individualised sleep diaries completed by carers. Other measures used included carer sleep quality rating and morning sleepiness rating (Gunning & Espie [2003](#jir12587-bib-0015){ref-type="ref"}). Richings and Feroz‐Nainar ([2010](#jir12587-bib-0041){ref-type="ref"}) relied on the difficulties being verbally reported to clinicians. Short and Carpenter ([1998](#jir12587-bib-0045){ref-type="ref"}) did not specify how sleep difficulties were measured. Stenfert‐Kroese and Thomas (2006) utilised participant self‐report for frequency of nightmares per week. Braam *et al*. ([2008](#jir12587-bib-0006){ref-type="ref"}) used a diary completed by a patient or carer focusing on sleep onset latency, number of night wakes, sleep onset time, wake up time, number and duration of night wakes and total sleep time. Ward *et al*. ([2015](#jir12587-bib-0054){ref-type="ref"}) utilised carer verbal reports and in some cases a sleep diary.

Three studies assessed the differences between baseline and follow up statistically (Gunning & Espie [2003](#jir12587-bib-0015){ref-type="ref"}; Braam *et al*. [2008](#jir12587-bib-0006){ref-type="ref"}; Hylkema & Vlaskamp [2009](#jir12587-bib-0019){ref-type="ref"}), two created categories according to whether they felt participants\' sleep had improved (Didden *et al*. [2002](#jir12587-bib-0011){ref-type="ref"}; Hare *et al*. [2008](#jir12587-bib-0018){ref-type="ref"}) and four assessed differences qualitatively (Short & Carpenter [1998](#jir12587-bib-0045){ref-type="ref"}; Stenfert‐Kroese & Thomas [2006](#jir12587-bib-0046){ref-type="ref"}; Richings & Feroz‐Nainar [2010](#jir12587-bib-0041){ref-type="ref"}; Ward *et al*. [2015](#jir12587-bib-0054){ref-type="ref"}).

As defined by the International Classification for Diseases -- 10th Revision criteria for a sleep disorder, the amount, quality or timing of sleep is required to be affected (World Health Organisation [1992](#jir12587-bib-0058){ref-type="ref"}). Figure [2](#jir12587-fig-0002){ref-type="fig"} summarises the number of participants across nine sleep intervention studies in which the sleep onset latency, duration and number of night wakes were recorded prior and after intervention. Sleep onset latency was only recorded in 58 participants, sleep duration was measured in 49 participants and number of night wakes was reported in 16 participants across all included studies.

![Reported change in key domains.](JIR-63-372-g002){#jir12587-fig-0002}

Interventions for sleep difficulties {#jir12587-sec-0016}
------------------------------------

Across the nine studies, interventions were not directly comparable. Either interventions varied across studies or the outcome measures used were different. The following is a summary of the main intervention methodologies evaluated in the included articles. Melatonin

Melatonin was used in four studies and a total of 40 participants in varying doses (2.5--12 mg; Braam *et al*. [2008](#jir12587-bib-0006){ref-type="ref"}; Hare *et al*. [2008](#jir12587-bib-0018){ref-type="ref"}; Richings & Feroz‐Nainar [2010](#jir12587-bib-0041){ref-type="ref"}; Ward *et al*. [2015](#jir12587-bib-0054){ref-type="ref"}). Braam *et al*. ([2008](#jir12587-bib-0006){ref-type="ref"}), which had a low risk of bias, identified that in eleven adult participants, 5 mg of melatonin was significantly (difference in change 29.48; *P* \< 0.01) more effective than a placebo (*N* = 10) at decreasing sleep onset latency. Ward *et al*. ([2015](#jir12587-bib-0054){ref-type="ref"}) had a serious risk of bias in the reported result, which identified 'mild', 'good' and 'excellent' improvements in 15 of the 23 adult participants who were prescribed between 2.5 and 10 mg of melatonin. In one case series with 'critical' risk of bias, all three participants stopped taking melatonin due to agitation (Richings & Feroz‐Nainar [2010](#jir12587-bib-0041){ref-type="ref"}). The final case series with three participants did not report enough information to make an informed decision about risk of bias (Hare *et al*. [2008](#jir12587-bib-0018){ref-type="ref"}). Improvements in sleep duration were noted in two of the three participants; however, conclusions about overall efficacy could not be established (Hare *et al*. [2008](#jir12587-bib-0018){ref-type="ref"}). Functional assessment

One study identified completed a functional assessment (through interviews and behaviour recording) and implemented an extinction intervention one 25‐year‐old (Didden *et al*. [2002](#jir12587-bib-0011){ref-type="ref"}). Extinction involves removing a reinforcer that maintains a behaviour (Didden *et al*. [2002](#jir12587-bib-0011){ref-type="ref"}). This found a decrease in 'night time disruption'; however, it was unclear if this increased sleep quality across other domains such as latency or duration (Didden *et al*. [2002](#jir12587-bib-0011){ref-type="ref"}). Mixed methods

Two studies used multiple or specific methods depending on the presenting sleep difficulty (Gunning & Espie [2003](#jir12587-bib-0015){ref-type="ref"}; Hylkema & Vlaskamp [2009](#jir12587-bib-0019){ref-type="ref"}). The intervention components utilised with nine participants identified by Gunning and Espie ([2003](#jir12587-bib-0015){ref-type="ref"}) were 'optimal scheduling', 'sleep hygiene', 'stimulus control', 'relaxation', 'light therapy' and 'cognitive behaviour therapy'. Six of the nine intervention packages produced a statistically significant effect on one of the outcome measures evaluated with varying effect sizes and levels of significance (Gunning & Espie [2003](#jir12587-bib-0015){ref-type="ref"}). Hylkema and Vlaskamp ([2009](#jir12587-bib-0019){ref-type="ref"}) utilised methods agreed on by a multi‐disciplinary team including varying activities, different daily routines, sleep scheduling and other with 34 participants. Statistically significant (*P* \< 0.001) improvements were noted in sleep efficiency and latency (Hylkema and Vlaskamp [2009](#jir12587-bib-0019){ref-type="ref"}). Other

Light therapy was used in one case study (Short & Carpenter [1998](#jir12587-bib-0045){ref-type="ref"}). Risk of bias was unable to be established due to lack of information. The authors reported that following 2 weeks, sleep patterns were reported to be normal and remained stable (Short & Carpenter [1998](#jir12587-bib-0045){ref-type="ref"}). Imagery rehearsal is the final intervention used in a case series with two participants (Stenfert‐Kroese & Thomas [2006](#jir12587-bib-0046){ref-type="ref"}). The participants reported no further nightmares following 2 weeks of intervention and at 6 months (Stenfert‐Kroese & Thomas [2006](#jir12587-bib-0046){ref-type="ref"}).

Discussion {#jir12587-sec-0017}
==========

Primary findings {#jir12587-sec-0018}
----------------

This systematic review aimed to identify if sleep interventions in adults with an ID improved sleep. Across all reviewed studies, seven reported that sleep interventions improved the sleep of their participants. However, there was a notable heterogeneity between studies in terms of sleep assessments, population studied, sleep intervention utilised, outcome reported, medications reported and analysis of results. This heterogeneity makes it difficult to synthesise a clear message about which sleep interventions work well for adults with an ID. Furthermore, findings from this study also indicated that the overall quality of studies in this field is low. Of the included studies, only one was evaluated to have an overall low risk of bias. The remaining studies had a serious to critical risk of bias.

It is not surprising that there is a perception that sleep difficulties in this population cannot be changed (O\'Reilly [1995](#jir12587-bib-0037){ref-type="ref"}; Wiggs & Stores [1996](#jir12587-bib-0055){ref-type="ref"}; Symons, Davis & Thompson [2000](#jir12587-bib-0048){ref-type="ref"}). Adding to the complications, the methods identifying sleep difficulties varied significantly. Actigraphy has been correlated with polysomnography and indicated as an objective measure of sleep in both drug and non‐pharmacological interventions (Sadeh [2011](#jir12587-bib-0043){ref-type="ref"}; Mantua, Gravel & Spencer [2016](#jir12587-bib-0029){ref-type="ref"}; Riemann *et al*. [2017](#jir12587-bib-0042){ref-type="ref"}). Despite the weight of evidence and a population who often cannot verbally report their experience, only two studies with 37 adults utilised actiwatches (Hare *et al*. [2008](#jir12587-bib-0018){ref-type="ref"}; Hylkema & Vlaskamp [2009](#jir12587-bib-0019){ref-type="ref"}; Martin & Hakim [2011](#jir12587-bib-0030){ref-type="ref"}).

Sleep hygiene and behavioural interventions {#jir12587-sec-0019}
-------------------------------------------

Despite several published randomised trials of behavioural interventions with children, no high‐quality studies have assessed behavioural interventions in adult populations with an ID (Wiggs & Stores [1998](#jir12587-bib-0056){ref-type="ref"}; Montgomery, Stores & Wiggs [2004](#jir12587-bib-0032){ref-type="ref"}).

Current interventions that authors have indicated efficacy amongst some sleep parameters and participants in the current literature include optimal night time or sleep scheduling, different daily routines, varying activities, sleep hygiene, stimulus control, relaxation, light therapy and cognitive behaviour therapy (Gunning & Espie [2003](#jir12587-bib-0015){ref-type="ref"}; Hylkema & Vlaskamp [2009](#jir12587-bib-0019){ref-type="ref"}). Gunning and Espie ([2003](#jir12587-bib-0015){ref-type="ref"}) specified criteria for the use of specific interventions. Hylkema and Vlaskamp ([2009](#jir12587-bib-0019){ref-type="ref"}) relied on an MDT decision‐making process, leading to a lack of clarity about which interventions are indicated or effective for specific sleep difficulties. Despite being recommended, no functional analysis procedure has been identified in the current review for behaviours that challenge that impact on sleep or as part of a sleep intervention study (Wiggs & Stores [1998](#jir12587-bib-0056){ref-type="ref"}; Iwata & Dozier [2008](#jir12587-bib-0022){ref-type="ref"}; National Institute for Health and Care Excellence [2015](#jir12587-bib-0035){ref-type="ref"}). However, functional assessments have shown an initial benefit, but more studies investigating this with a variety of functions for behaviour are necessary (Didden *et al*. [2002](#jir12587-bib-0011){ref-type="ref"}).

Melatonin {#jir12587-sec-0020}
---------

Melatonin was the only medication evaluated in the current review for sleep difficulties in adults with an ID. Although the highest quality evidence indicates benefits in sleep onset latency for the use of melatonin in the population, potential agitation, aggression and restless were noted in a small number of cases (Braam *et al*. [2008](#jir12587-bib-0006){ref-type="ref"}; Hare *et al*. [2008](#jir12587-bib-0018){ref-type="ref"}; Richings & Feroz‐Nainar [2010](#jir12587-bib-0041){ref-type="ref"}; Ward *et al*. [2015](#jir12587-bib-0054){ref-type="ref"}). Similar mixed results in evidence have been found by Braam *et al*. ([2009](#jir12587-bib-0007){ref-type="ref"}) in a meta‐analysis for the use of melatonin. These mixed results could be attributable to individual differences in receptor sensitivity as a causative factor amongst adults with an ID (Pandi‐Perumal *et al*. [2008](#jir12587-bib-0038){ref-type="ref"}).

Future research and clinical implications {#jir12587-sec-0021}
-----------------------------------------

The goal of this study was to examine the effectiveness of sleep interventions on sleep in adults with an ID. There is evidence, however, that sleep improvement can be a secondary consequence of mental health or lifestyle interventions (Altabet, Newman & Watson‐Johnson [2001](#jir12587-bib-0001){ref-type="ref"}; Biswas, Bhaumik & Branford [2001](#jir12587-bib-0004){ref-type="ref"}; Verhoeven, Egger, Willemsen, de Leijer & Kleefstra [2012](#jir12587-bib-0051){ref-type="ref"}; Wilhite, Biren & Spencer [2012](#jir12587-bib-0057){ref-type="ref"}; Majeske, Garakani, Maloutas, Bryson & Kellner [2013](#jir12587-bib-0028){ref-type="ref"}). As having an ID is frequently co‐morbid with other physical, behavioural and mental health conditions, sleep disruption is often an indirect consequence of co‐morbidity. For instance, results from studies focusing on fitness, depression and bipolar disorder indicate positive effects on sleep following interventions (Altabet *et al*. [2001](#jir12587-bib-0001){ref-type="ref"}; Wilhite *et al*. [2012](#jir12587-bib-0057){ref-type="ref"}; Majeske *et al*. [2013](#jir12587-bib-0028){ref-type="ref"}; Hamers, Festen & Hermans [2018](#jir12587-bib-0016){ref-type="ref"}). This indicates that the improvement of sleep in adults with an ID may involve a careful consideration of co‐occurring morbidities and what works for those morbidities. While investigating sleep improvement as an indirect improvement of other interventions was beyond the scope of this review, a broader review on interventions and sleep improvement in adults with ID could represent an interesting avenue for future research. In addition, including individual with co‐morbid mental health conditions and of course children with ID would also provide more information regarding the best interventions for sleep disturbances.

The use of melatonin and other medications that are commonly prescribed lead to polypharmacy in practice for sleep difficulties that may make evaluating individual components more difficult (Lake, Balogh & Lunsky [2012](#jir12587-bib-0024){ref-type="ref"}; National Institute for Health and Care Excellence [2013](#jir12587-bib-0034){ref-type="ref"}; Ward *et al*. [2015](#jir12587-bib-0054){ref-type="ref"}). In the UK, in line with stopping over medicating people with learning disability (<https://www.england.nhs.uk/learning-disabilities/improving-health/stomp>/), standardised pathways and medicating practices should be considered for treating sleep along with mental health conditions. Reducing variations in prescribing practices across a larger sample should be considered to strengthen the evidence for medication in sleep difficulties.

As heterogeneous data collected throughout studies have hindered a clear synthesis of efficacy, the use of a standardised ID sleep diary or actigraphy should be used in clinical practice and research (Riemann *et al*. [2017](#jir12587-bib-0042){ref-type="ref"}). There is also a need to compare medications, such as melatonin, and function‐based behavioural interventions to 'treatment as usual' for sleep difficulties in adults with ID (Asaria, Griffin & Cookson [2016](#jir12587-bib-0002){ref-type="ref"}). This should also take into account differences in presenting problems including physical and mental health concerns (Benca [2005](#jir12587-bib-0003){ref-type="ref"}; Matson *et al*. [2007](#jir12587-bib-0031){ref-type="ref"}; Walker [2009](#jir12587-bib-0053){ref-type="ref"}; Freeman *et al*. [2017](#jir12587-bib-0013){ref-type="ref"}).

Strengths and limitations {#jir12587-sec-0022}
-------------------------

The strengths of this study are that it is the first to systematically assess sleep interventions for adults with an ID. The present study searched a wide variety of electronic databases in the search criteria with a large variety of search terms. Unfortunately, the ability to draw robust conclusions about the potential efficacy of interventions are significantly hindered by the heterogeneity of data and low quality of included studies. The use of a randomised study while using the ROBINS‐I is also a potential limitation as it may underestimate the risk of bias of that particular study. This may indicate that there is a stronger evidence base for the use of melatonin that may not always be indicated. There is also a risk of publication and language biases for current literature.

Conclusions {#jir12587-sec-0023}
===========

The evidence for assessing the effectiveness of sleep interventions for adults with an ID has significant heterogeneity and was generally of poor quality. Because of the paucity of evidence, recommendations when adults with an ID present with a sleep difficulty or sleep disorder relies on clinicians\' anecdotal evidence. However, there is an opportunity to research standardised interventions using actigraphy and a standardised sleep diary in order to address heterogeneity. In addition, medication rationalisation, epilepsy optimisation and regular health checks should be undertaken thoroughly to manage additional causes of poor sleep. Clinicians should also, where possible, screen for sleep difficulties following referrals for behaviours that challenge or mental health disorders when not responding to typical interventions.
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